PRINCETON, N.J., Jan. 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Biotech Showcase 2009 in San Francisco. Mr.

Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings PRINCETON, N.J., Dec.

Celator Pharmaceuticals has announced that the FDA has granted orphan drug designation to CPX-351 liposome injection for the treatment of acute myeloid leukemia. Celator is currently preparing to conduct two randomized Phase II studies with CPX-351.

Celator Pharmaceuticals, which develops novel products based on proven combinations of chemotherapeutic drugs, has raised in excess of $22.5 million in a series C private equity financing.

Celator Pharmaceuticals has reported positive results from its CPX-1 Phase II clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex technology.